Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | CNR2 | P34972 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 2/20 | 0.46 |
| ▸ | CFTR | P13569 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10273451 | 0.83 | ALDH1A1 (0.65) | KMT2AMEN1ALDH1A1PKMLMNA | |
| SCHEMBL4979124 | 0.78 | IRAK4 (0.53) | KMT2AMEN1CYP1A2ALDH1A1PKM | |
| SCHEMBL15166271 | 0.76 | ALDH1A1 (0.68) | KMT2AMEN1ALDH1A1PKMLMNA | |
| SCHEMBL2016798 | 0.76 | KDM4E (0.44) | KMT2AMEN1CYP1A2ALDH1A1PKM | |
| SCHEMBL17199219 | 0.74 | MAPT (0.53) | KMT2AMEN1CYP1A2ALDH1A1LMNA | |
| SCHEMBL10466021 | 0.74 | CYP1A2 (0.48) | KMT2AMEN1CYP1A2ALDH1A1PKM | |
| SCHEMBL10466034 | 0.74 | PKM (0.50) | KMT2AMEN1CYP1A2ALDH1A1PKM | |
| SCHEMBL3070815 | 0.73 | CYP19A1 (0.55) | KMT2AMEN1ALDH1A1PKMLMNA | |
| SCHEMBL31349412 | 0.73 | LMNA (0.51) | KMT2AMEN1CYP1A2ALDH1A1PKM | |
| SCHEMBL4980895 | 0.73 | MEN1 (0.53) | KMT2AMEN1CYP1A2PKMLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7338959-B2 | Diamino-pyrimidines and their use as angiogenesis inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2008-03-04 | — | — | US | disclosed |
| US-20050234083-A1 | Diamino-pyrimidines and their use as angiogenesis inhibitors | SMITHKLINE BEECHAM CORPORATION | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234083-A1 | Diamino-pyrimidines and their use as angiogenesis inhibitors | TIE1, TEK, KDR | KMT2A 366/4885MEN1 1400/4885CYP1A2 2715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.